ArticleGut and liver2016
Field Cancerization in Sporadic Colon Cancer.
Article in Gut and liver, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples.International journal of colorectal disease · 2021Pooled it
- Trial
- Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer.Nature reviews. Cancer · 2025Review
- Genome-wide DNA methylation profiles of colorectal tumors in Lynch syndrome and familial adenomatous polyposis.Clinical epigenetics · 2025Article
- Analysis of LINE-1 DNA Methylation in Colorectal Cancer, Precancerous Lesions, and Adjacent Normal Mucosa.Medicina (Kaunas, Lithuania) · 2025Article
- The diagnostic efficiency of tissue factor pathway inhibitor 2 methylation in the detection of colorectal cancer: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2025Article
- Pharmacological modulation of mitochondrial function as novel strategies for treating intestinal inflammatory diseases and colorectal cancer.Journal of pharmaceutical analysis · 2025Review
- Variability in non-tumor areas of colorectal cancer patients as revealed by endoscopic intestinal step biopsies.Molecular cancer · 2024Article
- Epigenome-wide methylation analysis of colorectal carcinoma, adenoma and normal tissue reveals novel biomarkers addressing unmet clinical needs.Clinical epigenetics · 2023Article
- miR-23a-3p promotes the development of colon cancer by inhibiting the expression of NDRG4.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Article
- Discovery and validation of tissue-specific DNA methylation as noninvasive diagnostic markers for colorectal cancer.Clinical epigenetics · 2022Article
- Colon Cancer-Related Genes Identification and Function Study Based on Single-Cell Multi-Omics Integration.Frontiers in cell and developmental biology · 2021Article
- Role of Endoscopic Resection Versus Surgical Resection in Management of Malignant Colon Polyps: a National Cancer Database Analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.BMC cancer · 2019Article
- A qualitative transcriptional signature for the early diagnosis of colorectal cancer.Cancer science · 2019Article
- Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.Scientific reports · 2019Article
- Identification of differentially expressed genes regulated by methylation in colon cancer based on bioinformatics analysis.World journal of gastroenterology · 2019Article
- Mlh1 deficiency in normal mouse colon mucosa associates with chromosomally unstable colon cancer.Carcinogenesis · 2018Article
- FBI-1 mRNA in normal mucosa is an independent prognostic factor in colorectal cancer patients.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAberrant DNA methylation has a specific role in field cancerization. Certain molecular markers, including secreted frizzled-related protein 2 (SFRP2), tissue factor pathway inhibitor 2 (TFPI2 ), N-Myc downstream-regulated gene 4 (NDRG4) and bone morphogenic protein 3 (BMP3), have previously been shown to be hypermethylated in colorectal cancer (CRC). We aim to examine field cancerization in CRC based on the presence of aberrant DNA methylation in normal-appearing tissue from CRC patients.
methodsWe investigated promoter methylation in 34 CRC patients and five individuals with normal colonoscopy results. CRC patients were divided into three tissue groups: tumor tissue, adjacent and nonadjacent normal-appearing tissue. The methylation status (positive: methylation level >20%) of SFRP2 , TFPI2 , NDRG4 , and BMP3 promoters was investigated using methylation-specific PCR.
resultsThe methylation frequencies of the SFRP2 , TFPI2 , NDRG4 and BMP3 promoters in tumor/adjacent/nonadjacent normal-appearing tissue were 79.4%/63.0%/70.4%, 82.4%/53.6%/60.7%, 76.5%/61.5%/69.2%, 41.2%/35.7%/50.0%, respectively. The methylation levels of the SFRP, TFPI2, NDRG4 and BMP3 promoters in tumor tissues were significantly higher than those in normal-appearing tissue (SFRP2, p=0.013; TFPI2, p<0.001; NDRG4, p=0.003; BMP3, p=0.001). No significant correlation was observed between the methylation levels of the promoters and the clinicopathological variables.
conclusionsThe field effect is present in CRC and affects both the adjacent and nonadjacent normal-appearing mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.